FDA Panel Meeting for Nymox PMA Application Expected in July

Nymox Pharmaceutical announced that it has been informed that the company's premarket approval (PMA) application to FDA concerning a kit version of the company's AlzheimAlert urine test will be going forward to a presentation before a panel of the Medical Devices Advisory Committee which is expected in July. This step follows the submission to the FDA of further data and analyses by the company.

()a href="http://www.genengnews.com/news/bnitem.aspx?name=536609XSL_NEWSML_TO_NEWSML_WEB.xml" target="_blank">Genetic Engineering News